Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

123.34 USD +1.06 (+0.87%)
Official Closing Price Updated: 6:07 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ligand Pharm

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Keysight Technologies Set to Join S&P 500; Ligand Pharmaceuticals to Join S&P MidCap 400; Marcus & Millichap and Arcosa to Join S&P SmallCap 600
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: 
From PR Newswire
Analysis: Positioning to Benefit within Ligand Pharmaceuticals, AptarGroup, Unifirst, Universal, AutoZone, and Churchill Downs — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ligand Pharmaceuticals... 
From GlobeNewswire News Releases
Ligand to Report Third Quarter 2018 Results on November 8th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2018 financial results on November 8, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and... 
From Business Wire News Releases
Ligand Announces the Close of its Acquisition of Vernalis
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its acquisition of Vernalis plc has successfully closed and Vernalis will now operate as a subsidiary of Ligand. Vernalis is a... 
From Business Wire News Releases
Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, announced today the... 
From GlobeNewswire News Releases
Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer
Linical Accelovance Group will serve as research partner for study that compares lasofoxifene to fulvestrant 
From GlobeNewswire News Releases
Fr. Emmanuel Lemelson Responds to SEC Charges
Rev. Fr. Emmanuel Lemelson, the Chief Investment Officer of Lemelson Capital Management, today responded to a civil complaint filed by the United States Securities and Exchange Commission in the United... 
From PR Newswire
Ligand to Participate in H.C. Wainwright 20th Annual Global Investment Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in H.C. Wainwright 20th Annual Global Investment Conference in New York City. Presentation... 
From Business Wire News Releases
Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Vernalis plc (LSE: VER) announce that Ligand has declared its firm intention to acquire the entire issued and to be issued shares of Vernalis... 
From Business Wire News Releases
Ligand Reports Second Quarter 2018 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2018, and provided an operating forecast and program updates. Ligand... 
From Business Wire News Releases
Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
Apricus Biosciences, Inc. (Nasdaq: APRI) announced the signing of a definitive agreement to merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction.... 
From GlobeNewswire News Releases
Rev. Fr. Emmanuel Lemelson Calls on Congress, Office of Inspector General to Investigate SEC Failures
Failure to prosecute Alleged Multi-Year Accounting and Securities Fraud at Ligand Pharmaceuticals (NASDAQ: LGND) Diminishes SEC Credibility, Warrants Investigation 
From PR Newswire
Ligand to Report Second Quarter 2018 Results on August 6th
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report second quarter 2018 financial results on August 6, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and... 
From Business Wire News Releases
Analysis: Positioning to Benefit within EMCOR Group, Ring Energy, A. O. Smith, bluebird bio, Ligand Pharmaceuticals, and Synovus Financial — Research Highlights Growth, Revenue, and Consolidated Resul
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EMCOR Group, Inc.... 
From GlobeNewswire News Releases
Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has received $47 million as a result of signing an amendment relating to its OmniAb platform agreement with WuXi Biologics (“WuXi Bio”,... 
From Business Wire News Releases
Ligand Prices Offering of $650 Million of Convertible Senior Notes
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today the pricing of $650 million aggregate principal amount of 0.75% convertible senior notes due 2023 in a private offering to qualified... 
From Business Wire News Releases
Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it intends to offer, subject to market conditions and other factors, $650 million aggregate principal amount of convertible... 
From Business Wire News Releases
New Research Coverage Highlights Assurant, Williams Partners, Atmos Energy, Nationstar Mortgage, Applied Materials, and Ligand Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Assurant, Inc. (NYSE:AIZ),... 
From GlobeNewswire News Releases
Ligand to Participate in Upcoming Investor Conferences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: 
From Business Wire News Releases
Ligand Reports First Quarter 2018 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2018, and provided an operating forecast and program updates. Ligand management... 
From Business Wire News Releases
Ligand to Report First Quarter 2018 Results on May 8th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2018 financial results on May 8, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and... 
From Business Wire News Releases
Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into an agreement with venBio Partners, a venture capital group focused on building and funding portfolio companies with... 
From Business Wire News Releases
Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Roivant Sciences exclusive global rights to develop and commercialize LGD-6972, Ligand’s... 
From Business Wire News Releases
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: 
From Business Wire News Releases
Ligand Reports Fourth Quarter and Full Year 2017 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2017, and provided an operating forecast and program updates. Ligand... 
From Business Wire News Releases
Investor Expectations to Drive Momentum within A. O. Smith, Jacobs Engineering Group, Ligand Pharmaceuticals, National CineMedia, American Renal Associates, and Acco Brands — Discovering Underlying Fa
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of A. O. Smith Corporation... 
From GlobeNewswire News Releases
Ligand to Report Fourth Quarter and Full Year 2017 Results on February 21st
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2017 financial results on February 21, 2018. Ligand’s CEO John Higgins, President and COO... 
From Business Wire News Releases
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Ferring Pharmaceuticals
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals. Under the license, Ferring will be able to... 
From Business Wire News Releases
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces initiation of a program to develop contrast agents with reduced renal toxicity. Contrast agents are injectable solutions used during... 
From Business Wire News Releases
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals. Under the license, Glenmark will be able to use... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.